RGNX
Regenxbio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RGNX
Regenxbio Inc.
A biotechnology company that develops gene therapies for treating rare genetic diseases
Biological Technology
07/16/2008
09/17/2015
NASDAQ Stock Exchange
353
12-31
Common stock
9804 Medical Center Drive
, Rockville
, MD 20850
--
Regenxbio Inc., was founded on July 16, 2008. The company is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus gene therapies. In AAV gene therapy, viral genes are removed from the AAV, a small non-pathogenic cold virus, to produce a biological delivery vector called a vector. The sequence of the therapeutic gene is then inserted to form a recombinant vector. The company's proprietary AAV gene delivery platform includes exclusive rights to over 100 new AAV vectors, including AAV7, AAV8, AAV9 and AAVrh 10. The company's mission is to transform the lives of patients from serious diseases with significant unmet medical needs to direct in vivo gene therapy products through development and commercialization, or in vivo, based on its NAV technology platform.
Earnings Call
Q1/2025
Estimate EPS0.49
Actual EPS0.12
Estimate Revenue105.35M
Actual Revenue89.01M
Contradictions Unveiled: Navigating Regulatory Challenges and Clinical Data for RGX-121 in 2025
May 20,2025 07:15
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-1.05
Actual EPS-1.38
Estimate Revenue40.87M
Actual Revenue21.36M
Regenxbio's Q2 2025: Key Contradictions on RGX-121 Approval, Manufacturing Plans, and Pivotal Study Design
Aug 08,2025 09:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
RGNX has released its 2025 Q3 earnings. EPS was reported at -1.2, versus the expected -1.3, beating expectations. The chart below visualizes how RGNX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RGNX has released its 2025 Q3 earnings report, with revenue of 29.73M, reflecting a YoY change of 22.88%, and net profit of -61.94M, showing a YoY change of -3.93%. The Sankey diagram below clearly presents RGNX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
